Sanofi-Aventis wins in gaining US court ban in Sun generic Eloxatin case
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis says that, under a US court order, Sun Pharmaceuticals will be required to cease selling its infringing generic version of Eloxatin (oxaliplatin) by 30 June. The ruling makes Sun the seventh generics maker to agree to take a generic version of oxaliplatin off the US market from this June until August 2012.